Cis-Diamminedichloroplatinum Ii
Cancer Of Unknown Primary Site
Explore 18 assets in Cancer Of Unknown Primary Site →Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
Emory University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02897375CT.gov Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors | — | Completed | — | — | — |
NCT02116530CT.gov Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy | — | Completed | — | — | — |
NCT02194049CT.gov Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer | — | Completed | — | — | — |
NCT01366144CT.gov Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | — | Active Not Recruiting | — | — | — |
NCT01233505CT.gov Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT00949949CT.gov Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy | — | Completed | — | — | — |
NCT00544596CT.gov R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00573690CT.gov Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors | — | Completed | — | — | — |
NCT00415324CT.gov Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00423865CT.gov Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
Show 25 more trialsShow fewer
NCT00387608CT.gov ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer | — | Completed | — | — | — |
NCT00084812CT.gov Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT00072332CT.gov Edotecarin and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT00047047CT.gov Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00046917CT.gov Combination Chemotherapy in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00006464CT.gov UCN-01 and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT00012194CT.gov 7-hydroxystaurosporine and Cisplatin in Treating Patients With Advanced Malignant Solid Tumors | — | Terminated | — | — | — |
NCT00024323CT.gov Combination Chemotherapy in Treating Patients With Advanced Cancer | — | Completed | — | — | — |
NCT00550901CT.gov Dexrazoxane and Cisplatin in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00009932CT.gov Combination Chemotherapy in Treating Patients With Solid Tumors | — | Unknown | — | — | — |
NCT00016874CT.gov 3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer | — | Completed | — | — | — |
NCT00006000CT.gov SU5416, Irinotecan, and Cisplatin in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00005819CT.gov Combination Chemotherapy in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00006036CT.gov Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT00004189CT.gov Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer | — | Completed | — | — | — |
NCT00004063CT.gov Cisplatin, Gemcitabine, Interferon Alfa, and Hyperthermia in Treating Patients With Advanced Cancer | — | Unknown | — | — | — |
NCT00003690CT.gov Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00003242CT.gov Bryostatin 1 Plus Paclitaxel and Cisplatin in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00003269CT.gov Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors | — | Completed | — | — | — |
NCT00003132CT.gov Bryostatin 1 Plus Cisplatin in Treating Patients With Metastatic or Unresectable Cancer | — | Completed | — | — | — |
NCT00003108CT.gov Cisplatin Plus Bryostatin 1 in Treating Patients With Advanced Cancer | — | Completed | — | — | — |
NCT00003144CT.gov Chemotherapy and Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors | — | Completed | — | — | — |
NCT00003004CT.gov Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors | — | Completed | — | — | — |
NCT00004875CT.gov Heparin or Enoxaparin in Patients With Cancer | — | Completed | — | — | — |
NCT00005996CT.gov SU5416 Combined With Gemcitabine and Cisplatin in Treating Patients With Advanced Solid Tumors | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer Of Unknown Primary Site
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cis-Diamminedichloroplatinum Ii (this asset) | Emory University | P3 | BB · 70 |
| Amifostine | M.D. Anderson Cancer Center | P4 | BBB |
| Nepenthe | M.D. Anderson Cancer Center | P4 | BBB |
| Dexasone | Alliance for Clinical Trials in Oncology | P3 | BBB |
| Etoposide | University of California, Davis | P2/3 | BBB |
| Cyclophosphamide | M.D. Anderson Cancer Center | P3 | BBB |
| Irinotecan | University of Chicago | P2 | BBB |
| Nogitecan | National Cancer Institute (NCI) | P2 | BBB |
| Melphalan | City of Hope Medical Center | P2/3 | BBB |
+42 more in the Cancer Of Unknown Primary Site cohort
Other indications for Cis-Diamminedichloroplatinum Ii
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Squamous Cell Lung Carcinoma | — | P4 | BBB · 78 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 77 |
| Adenocarcinoma | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cis-Diamminedichloroplatinum Ii in Cancer Of Unknown Primary Site. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cis-diamminedichloroplatinum-ii-cancer-of-unknown-primary-site
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →